Evaluation of the safety, pharmacokinetics and treatment effects of an αvβ3 integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases

Asia-Pacific Journal of Clinical Oncology

Volumn 6, Issue 1, 2010, Pages 42-48

  Rosenthal, Mark A ^a   Davidson, Peter ^b   Rolland, Frederic ^c   Campone, Mario ^c   Xue, Lingling ^d   Han, Tae H ^d   Mehta, Anish ^d   Berd, Yuliya ^d   He, Weili ^d   Lombardi, Antonio ^d  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b Curt Medical Trials Trust   (New Zealand)

^c Centre Gauducheau Medicine Oncologie   (France)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

v 3 integrin; Bone metastasis; Prostate cancer

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CREATININE; MK 0429; PLACEBO; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BONE METASTASIS; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERHIDROSIS; MALE; MORNING DOSAGE; MULTICENTER STUDY; MUSCLE WEAKNESS; MYOPATHY; NAUSEA; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CROSS LINKING; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN DISEASE; SPINAL CORD COMPRESSION; TREATMENT DURATION;

AGED; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DOUBLE-BLIND METHOD; HUMANS; INTEGRINS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 77951212664     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2009.01266.x     Document Type: Article

References (13)

1. American Cancer Society overview: Prostate cancer. How many men get prostate cancer? 2007, http://www.cancer.org/docroot/CRI/content/CRI_2_2_1X_How_many_men_get_prostate_cancer_36.asp?sitearea=, American Cancer Society, Cited 2 July 2008, Available from URL:
2. Damber JE, Aus G. Prostate cancer. Lancet 2008, 371(9625):1710-21.
3. Saad F, Gleason DM, Murray R. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96:879-82.
4. Lipton A. The safety of zoledronic acid. Expert Opin Drug Saf 2007, 6:305-13.
5. Pidgeon GP, Tang K, Cai YL, Piasentin E, Honn KV. Overexpression of platelet-type 12-lipoxygenase promotes tumor cell survival by enhancing alpha(v) beta (3) and alpha(v) beta(5) integrin expression. Cancer Res 2003, 63:4258-67.
6. Brooks PC, Montgomery AM, Rosenfeld M. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-64.
7. Teitelbaum SL. Osteoclasts and integrins. Ann N Y Acad Sci 2006, 1068:95-9.
8. Dresner-Pollak R, Rosenblatt M. Blockade of osteoclast-mediated bone resorption through occupancy of the integrin receptor: a potential approach to the therapy of osteoporosis. J Cell Biochem 1994, 56:323-30.
9. Coleman RE. Skeletal complications of malignancy. Cancer 1997, 80(l):1588-94. Suppl
10. McKeage K, Keam SJ. Docetaxel in hormone-refractory metastatic prostate cancer. Drugs 2005, 65:2287-94.
11. Petrylak DP, Tangen CM, Hussain MHA. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-20.
12. Tannock IF, de Wit R, Berry WR. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: the TAX 327 investigators. N Engl J Med 2004, 351:1502-12.
13. Costa L, Demers LM, Gouveia-Oliveira A. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002, 20:850-6.